Jeffrey S Miller

List of Publications by Citations

325 papers	19,348 citations	72 h-index	131 g-index
338 ext. papers	23,152 ext. citations	5 avg, IF	6.84 L-index

#	Paper	IF	Citations
325	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood*, **2005**, 105, 3051-7	2.2	1258
324	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. *Blood*, **2011**, 117, 1061-70	2.2	812
323	Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. *Blood*, **2005**, 105, 1343-7	2.2	744
322	Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. *Immunity*, **2015**, 42, 443-56	32.3	454
321	Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. *Blood*, **2012**, 119, 2665-74	2.2	451
320	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. *Blood*, **2007**, 110, 3064-70	2.2	449
319	Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. *Blood*, **2010**, 116, 2411-9	2.2	437
318	Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. *Blood*, **2003**, 102, 1915-9	2.2	369
317	Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. *Blood*, **2009**, 113, 726-32	2.2	339
316	Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. *Blood*, **2002**, 100, 3825-7	2.2	318
315	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. *Cytotherapy*, **2011**, 13, 98-107	4.8	301
314	Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. *Science Translational Medicine*, **2011**, 3, 83ra41	17.5	272
313	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. *Blood*, **2014**, 123, 3855-63	2.2	265
312	Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. *Journal of Immunology*, **2012**, 189, 5082-8	5.3	253
311	Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. *Blood*, **2009**, 114, 4293-9	2.2	251
310	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. *Blood*, **2016**, 127, 1044-51	2.2	251
309	Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. *Blood*, **2012**, 119, 3064-72	2.2	233

308	Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. *Blood*, **2007**, 109, 5058-61	2.2	230
307	The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 876-84	4.7	215
306	IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. *Clinical Cancer Research*, **2016**, 22, 3440-50	12.9	202
305	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. *Lancet Oncology, The*, **2018**, 19, 694-704	21.7	201
304	Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. *Blood*, **2001**, 98, 705-13	2.2	197
303	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. *Blood*, **2018**, 131, 2515-2527	2.2	194
302	A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. *Blood*, **2007**, 110, 578-86	2.2	183
301	KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. *Blood*, **2005**, 106, 4370-6	2.2	181
300	Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. *PLoS ONE*, **2010**, 5, e15115	3.7	173
299	Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. *Experimental Hematology*, **1999**, 27, 1533-41	3.1	164
298	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. *Blood*, **2014**, 123, 3016-26	2.2	163
297	Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. *Journal of Immunology*, **2005**, 175, 5095-103	5.3	163
296	Single Adult Human CD34+/Lin−CD38− Progenitors Give Rise to Natural Killer Cells, B-Lineage Cells, Dendritic Cells, and Myeloid Cells. *Blood*, **1999**, 93, 96-106	2.2	163
295	Exploring the NK cell platform for cancer immunotherapy. *Nature Reviews Clinical Oncology*, **2021**, 18, 85-100	19.4	161
294	Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. *Molecular Cancer Therapeutics*, **2012**, 11, 2674-84	6.1	155
293	HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. *Journal of Virology*, **2009**, 83, 6798-805	6.6	149
292	Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. *Clinical Cancer Research*, **2013**, 19, 3844-55	12.9	146
291	Allogeneic natural killer cells for refractory lymphoma. *Cancer Immunology, Immunotherapy*, **2010**, 59, 1739-44	7.4	145

290	Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. *Journal of Immunology*, **2011**, 187, 6171-5	5.3	138
289	Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 1065-72	4.7	138
288	Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?. *Blood*, **2011**, 118, 5084-95	2.2	130
287	Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. *Blood*, **2009**, 113, 5628-34	2.2	130
286	Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. *International Immunology*, **2006**, 18, 1115-26	4.9	126
285	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. *Molecular Therapy*, **2016**, 24, 570-81	11.7	125
284	Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. *Blood*, **2008**, 112, 2847-57	2.2	123
283	Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. *Blood*, **2006**, 108, 3824-33	2.2	121
282	Clinical utility of natural killer cells in cancer therapy and transplantation. *Seminars in Immunology*, **2014**, 26, 161-72	10.7	119
281	Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. *Journal of Immunology*, **2014**, 192, 4592-600	5.3	114
280	First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. *Clinical Cancer Research*, **2007**, 13, 7119-25	12.9	114
279	The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. *Blood*, **2007**, 110, 1530-9	2.2	111
278	Use of allogeneic NK cells for cancer immunotherapy. *Immunotherapy*, **2011**, 3, 1445-59	3.8	105
277	Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 282-9	4.7	105
276	The biology of natural killer cells in cancer, infection, and pregnancy. *Experimental Hematology*, **2001**, 29, 1157-68	3.1	105
275	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. *Cancer Research*, **2016**, 76, 5696-5706	10.1	101
274	NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. *Blood*, **2011**, 118, 2784-92	2.2	100
273	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. *Clinical Cancer Research*, **2018**, 24, 1525-1535	12.9	95

272	Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. *Transfusion*, **2007**, 47, 520-8	2.9	93
271	NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 565-86	4.7	91
270	Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. *JCI Insight*, **2018**, 3,	9.9	91
269	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. *Blood Advances*, **2019**, 3, 1970-1980	7.8	90
268	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. *Clinical Cancer Research*, **2018**, 24, 5552-5561	12.9	89
267	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. *Clinical Cancer Research*, **2018**, 24, 1834-1844	12.9	88
266	Natural Killer (NK) Cells Are Functionally Abnormal and NK Cell Progenitors Are Diminished in Granulocyte Colony-Stimulating Factor–Mobilized Peripheral Blood Progenitor Cell Collections. *Blood*, **1997**, 90, 3098-3105	2.2	86
265	Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity. *Annals of Thoracic Surgery*, **2008**, 86, 1735-44	2.7	85
264	NK cells in therapy of cancer. *Critical Reviews in Oncogenesis*, **2014**, 19, 133-41	1.3	83
263	Natural killer-cell differentiation by myeloid progenitors. *Blood*, **2011**, 117, 3548-58	2.2	83
262	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. *Blood*, **2015**, 126, 1621-8	2.2	82
261	Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. *Journal of Clinical Oncology*, **2009**, 27, 3634-41	2.2	79
260	Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1271-3	4.7	77
259	Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. *Blood*, **2018**, 131, 1053-1062	2.2	76
258	Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 215-22	4.7	76
257	Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. *Methods in Molecular Biology*, **2016**, 1441, 333-46	1.4	76
256	Natural Killer Cells in Cancer Immunotherapy. *Annual Review of Cancer Biology*, **2019**, 3, 77-103	13.3	75
255	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. *Seminars in Immunology*, **2017**, 31, 64-75	10.7	74

254	Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. *Blood*, **2007**, 110, 2761-3	2.2	73
253	Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 612-21	4.7	72
252	GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. *Cancer Research*, **2017**, 77, 5664-5675	10.1	71
251	Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. *Cancer Journal (Sudbury, Mass.)*, **2015**, 21, 486-91	2.2	70
250	A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. *American Journal of Hematology*, **2014**, 89, 889-95	7.1	68
249	Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. *Blood*, **2020**, 135, 399-410	2.2	68
248	Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. *Blood*, **2012**, 119, 619-28	2.2	67
247	Natural killer cells: a review of manufacturing and clinical utility. *Transfusion*, **2013**, 53, 404-10	2.9	65
246	Therapeutic applications: natural killer cells in the clinic. *Hematology American Society of Hematology Education Program*, **2013**, 2013, 247-53	3.1	65
245	Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. *Journal of Clinical Investigation*, **2019**, 129, 3770-3785	15.9	65
244	The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). *Immunological Reviews*, **2014**, 258, 45-63	11.3	64
243	The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. *British Journal of Haematology*, **2009**, 147, 185-91	4.5	63
242	Epigenetic control of highly homologous killer Ig-like receptor gene alleles. *Journal of Immunology*, **2005**, 175, 5966-74	5.3	62
241	ARID5B regulates metabolic programming in human adaptive NK cells. *Journal of Experimental Medicine*, **2018**, 215, 2379-2395	16.6	61
240	iTRAQ is a useful method to screen for membrane-bound proteins differentially expressed in human natural killer cell types. *Journal of Proteome Research*, **2007**, 6, 644-53	5.6	61
239	161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. *Blood Advances*, **2018**, 2, 1459-1469	7.8	61
238	Epigenetic regulation of NK cell differentiation and effector functions. *Frontiers in Immunology*, **2013**, 4, 55	8.4	60
237	Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. *Cancer Biotherapy and Radiopharmaceuticals*, **2013**, 28, 274-82	3.9	59

236	Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. *JCI Insight*, **2017**, 2,	9.9	58
235	A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. *Molecular Therapy*, **2020**, 28, 52-63	11.7	58
234	Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1252-7	4.7	57
233	Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. *Lancet Haematology,the*, **2016**, 3, e87-98	14.6	56
232	Anti-HLA antibodies in double umbilical cord blood transplantation. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1704-8	4.7	56
231	NK cells--from bench to clinic. *Biology of Blood and Marrow Transplantation*, **2012**, 18, S2-7	4.7	55
230	Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). *Biology of Blood and Marrow Transplantation*, **2007**, 13, 1145-52	4.7	54
229	Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. *American Journal of Medicine*, **2001**, 110, 339-46	2.4	53
228	Cutting edge: KIR antisense transcripts are processed into a 28-base PIWI-like RNA in human NK cells. *Journal of Immunology*, **2010**, 185, 2009-12	5.3	52
227	Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. *Cancer Immunology, Immunotherapy*, **2010**, 59, 1877-1884	7.4	51
226	Human NK Cell Development: One Road or Many?. *Frontiers in Immunology*, **2019**, 10, 2078	8.4	50
225	Biology of natural killer cells in cancer and infection. *Cancer Investigation*, **2002**, 20, 405-19	2.1	50
224	Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 831-40	4.7	49
223	Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. *Cancer Research and Treatment*, **2017**, 49, 1140-1152	5.2	47
222	Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. *Clinical Cancer Research*, **2015**, 21, 1267-72	12.9	46
221	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. *Science Translational Medicine*, **2020**, 12,	17.5	46
220	A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 109-16	4.7	46
219	Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. *American Journal of Hematology*, **2007**, 82, 867-72	7.1	46

218	Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. *Cancer Immunology, Immunotherapy*, **2018**, 67, 483-494	7.4	46
217	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. *Cancer Immunology Research* , **2018**, 6, 766-775	12.5	46
216	Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. *American Journal of Hematology*, **2012**, 87, 953-6	7.1	45
215	Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 538-45	4.7	45
214	Ex Vivo Culture of CD34+/Lin/DRCells in Stroma-Derived Soluble Factors, Interleukin-3, and Macrophage Inflammatory Protein-1Maintains Not Only Myeloid But Also Lymphoid Progenitors in a Novel Switch Culture Assay. *Blood*, **1998**, 91, 4516-4522	2.2	45
213	Lineage relationships of human interleukin-22-producing CD56+ ROR+ innate lymphoid cells and conventional natural killer cells. *Blood*, **2013**, 121, 2234-43	2.2	44
212	Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. *Cytotherapy*, **2013**, 15, 1297-306	4.8	43
211	Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. *Science Translational Medicine*, **2015**, 7, 315ra191	17.5	41
210	Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1653-62	4.7	41
209	Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2004**, 10, 395-404	4.7	40
208	Adaptive NK cell reconstitution is associated with better clinical outcomes. *JCI Insight*, **2019**, 4,	9.9	40
207	Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. *Blood Advances*, **2019**, 3, 897-907	7.8	40
206	Diversification and Functional Specialization of Human NK Cell Subsets. *Current Topics in Microbiology and Immunology*, **2016**, 395, 63-94	3.3	39
205	Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 487-92	4.7	39
204	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. *Blood Advances*, **2018**, 2, 909-922	7.8	39
203	Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. *Gynecologic Oncology*, **2019**, 153, 149-157	4.9	38
202	A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1581-1589	4.7	38
201	Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 480-6	4.7	37

200	Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. *Experimental Hematology*, **2008**, 36, 598-608	3.1	37
199	HLA-haploidentical stem cell transplantation for hematologic malignancies. *Biology of Blood and Marrow Transplantation*, **2010**, 16, S57-63	4.7	36
198	Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker. *Oncotarget*, **2016**, 7, 73830-73844	3.3	36
197	Combined OX40L and mTOR blockade controls effector T cell activation while preserving T reconstitution after transplant. *Science Translational Medicine*, **2017**, 9,	17.5	35
196	National Cancer Institute© First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 443-54	4.7	35
195	The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element. *Blood*, **2009**, 113, 3245-53	2.2	35
194	Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. *Journal of Immunology*, **2008**, 181, 4507-15	5.3	35
193	Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 214-22	4.7	34
192	FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. *Biology of Blood and Marrow Transplantation*, **2005**, 11, 23-34	4.7	34
191	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. *Blood*, **2019**, 134, 1670-1682	2.2	33
190	Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. *Human Gene Therapy*, **2002**, 13, 979-88	4.8	33
189	Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. *Journal of Experimental Medicine*, **2014**, 211, 1079-91	16.6	32
188	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. *Cytotherapy*, **2017**, 19, 250-262	4.8	32
187	Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 1155-61	4.7	32
186	Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. *Blood*, **2016**, 128, 2568-2579	2.2	32
185	Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1602-1607	4.7	32
184	Use of natural killer cells as immunotherapy for leukaemia. *Best Practice and Research in Clinical Haematology*, **2008**, 21, 467-83	4.2	31
183	Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor. *Stem Cells and Development*, **1996**, 5, 475-83		31

182	Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation. *Journal of Immunology*, **2015**, 195, 4524-36	5.3	30
181	Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells. *Immunity*, **2018**, 48, 760-772.e4	32.3	30
180	Isolation and characterization of canine natural killer cells. *Veterinary Immunology and Immunopathology*, **2013**, 155, 211-7	2	30
179	Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. *Experimental Hematology*, **2000**, 28, 96-103	3.1	30
178	Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium. *Stem Cells and Development*, **1995**, 4, 149-58		30
177	ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment. *Journal of Virology*, **2018**, 92,	6.6	30
176	Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma **2018**, 6, 58		28
175	Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. *Molecular Therapy*, **2018**, 26, 1423-1434	11.7	28
174	Early Reconstitution of NK and □T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1152-1162	4.7	27
173	Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation. *European Journal of Immunology*, **2015**, 45, 2335-42	6.1	27
172	Killer immunoglobulin-like receptor transcriptional regulation: a fascinating dance of multiple promoters. *Journal of Innate Immunity*, **2011**, 3, 242-8	6.9	27
171	The biology of natural killer cells and implications for therapy of human disease. *Journal of Hematotherapy and Stem Cell Research*, **2001**, 10, 451-63		27
170	In vitro development of human Killer-Immunoglobulin Receptor-positive NK cells. *Methods in Molecular Biology*, **2010**, 612, 15-26	1.4	27
169	The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. *Journal of Immunology*, **2002**, 168, 643-50	5.3	26
168	Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. *Experimental Hematology*, **1999**, 27, 1519-27	3.1	25
167	Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation. *Journal of Immunology*, **2014**, 193, 3344-54	5.3	24
166	Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2008**, 31, 173-81	2.7	24
165	Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. *Cytokine*, **2018**, 107, 105-112	4	23

164	Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 173-82	4.7	23
163	Activated notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 183-94	4.7	23
162	Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. *Blood Reviews*, **2020**, 44, 100678	11.1	22
161	Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside. *Cancer Immunology Research*, **2019**, 7, 1742-1747	12.5	22
160	Myelodysplastic syndromes: the role of the immune system in pathogenesis. *Leukemia and Lymphoma*, **2011**, 52, 2045-9	1.9	22
159	Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. *Oncotarget*, **2018**, 9, 34810-34820	3.3	22
158	The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. *Current Topics in Microbiology and Immunology*, **2016**, 395, 225-43	3.3	21
157	Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 536-45	4.7	21
156	The role of autologous natural killer cells in chronic myelogenous leukemia. *Leukemia and Lymphoma*, **1997**, 27, 387-99	1.9	21
155	Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. *Biology of Blood and Marrow Transplantation*, **2005**, 11, 129-35	4.7	21
154	Single Adult Human CD34+/Lin−/CD38− Progenitors Give Rise to Natural Killer Cells, B-Lineage Cells, Dendritic Cells, and Myeloid Cells. *Blood*, **1999**, 93, 96-106	2.2	21
153	Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation. *Blood*, **2009**, 114, 4753-4; author reply 4754-5	2.2	20
152	Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. *Clinical Immunology*, **2005**, 117, 144-51	9	20
151	Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. *Frontiers in Immunology*, **2017**, 8, 1825	8.4	19
150	Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs. *Transplantation*, **2006**, 82, 23-9	1.8	19
149	BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs). *Blood*, **2003**, 101, 3527-33	2.2	19
148	FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies. *Blood*, **2019**, 134, 301-301	2.2	19
147	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. *Cancers*, **2020**, 12,	6.6	19

146	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. *Blood Advances*, **2020**, 4, 740-754	7.8	19
145	Functional NK cell repertoires are maintained through IL-2R and Fas ligand. *Journal of Immunology*, **2014**, 192, 3889-97	5.3	18
144	Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. *Journal of Immunotherapy*, **2019**, 42, 65-72	5	18
143	Successful "in-flight" activation of natural killer cells during long-distance shipping. *Transfusion*, **2013**, 53, 398-403	2.9	17
142	A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. *Leukemia*, **2021**, 35, 1586-1596	10.7	17
141	Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential?. *Cytotherapy*, **2009**, 11, 259-60	4.8	16
140	The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory. *Transfusion Medicine Reviews*, **2005**, 19, 217-28	7.4	16
139	FLT-3 Ligand and Marrow Stroma-Derived Factors Promote CD3, CD3, CD3, and RAG-2 Gene Expression in Primary Human CD34+LIN DR Marrow Progenitors. *Blood*, **1998**, 91, 1662-1670	2.2	16
138	Current strategies exploiting NK-cell therapy to treat haematologic malignancies. *International Journal of Immunogenetics*, **2018**, 45, 237	2.3	15
137	Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults. *British Journal of Haematology*, **2002**, 118, 101-7	4.5	14
136	Unraveling exhaustion in adaptive and conventional NK cells. *Journal of Leukocyte Biology*, **2020**, 108, 1361-1368	6.5	14
135	Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. *Blood Advances*, **2018**, 2, 1580-1584	7.8	14
134	Adoptive Therapy with T Cells/NK Cells. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 33-42	4.7	13
133	Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. *JCI Insight*, **2020**, 5,	9.9	13
132	Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. *Cancer Immunology Research*, **2020**, 8, 1139-1149	12.5	13
131	Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 153-160	4.7	12
130	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. *Frontiers in Immunology*, **2017**, 8, 675	8.4	12
129	A novel method for KIR-ligand typing by pyrosequencing to predict NK cell alloreactivity. *Clinical Immunology*, **2007**, 123, 272-80	9	12

128	Human natural killer cell microRNA: differential expression of MIR181A1B1 and MIR181A2B2 genes encoding identical mature microRNAs. *Genes and Immunity*, **2015**, 16, 89-98	4.4	11
127	Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. *Transfusion*, **2018**, 58, 1458-1467	2.9	11
126	Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?. *Clinical Cancer Research*, **2016**, 22, 5161-5163	12.9	11
125	Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2004**, 10, 171-7	4.7	11
124	Population dynamics of human activated natural killer cells in culture. *Biotechnology and Bioengineering*, **1994**, 43, 685-92	4.9	11
123	NK Cells and Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT). *Current Stem Cell Reports*, **2017**, 3, 301-311	1.8	10
122	T-cell factor-1 expression during human natural killer cell development and in circulating CD56(+) bright natural killer cells. *Experimental Hematology*, **2001**, 29, 499-506	3.1	10
121	Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. *Journal of Clinical Investigation*, **2020**, 130, 4652-4662	15.9	10
120	Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma. *Blood*, **2020**, 136, 8-8	2.2	10
119	Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. *Blood Advances*, **2020**, 4, 1350-1356	7.8	10
118	Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. *Cell Stem Cell*, **2021**, 28, 2062-2075.e5	18	10
117	Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab **2019**, 7, 70		9
116	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 126-133	4.7	9
115	Minimally invasive versus open Roux-en-Y gastric bypass: effect on immune effector cells. *Surgery for Obesity and Related Diseases*, **2009**, 5, 181-93	3	9
114	"Self"-reflection by KIR. *Blood*, **2009**, 114, 2-3	2.2	9
113	GTB-3550 TriKE for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts. *Blood*, **2020**, 136, 7-8	2.2	9
112	FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma. *Blood*, **2020**, 136, 4-5	2.2	9
111	Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells. *Blood*, **2008**, 112, 827-827	2.2	9

110	Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML. *Blood*, **2012**, 120, 894-894	2.2	9
109	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. *Blood Advances*, **2021**, 5, 1425-1436	7.8	9
108	Clinical production and therapeutic applications of alloreactive natural killer cells. *Methods in Molecular Biology*, **2012**, 882, 491-507	1.4	8
107	Therapy for chronic myelogenous leukemia with marrow transplantation. *Current Opinion in Oncology*, **1993**, 5, 262-9	4.2	8
106	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 56-62	4.7	7
105	Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2014**, 37, 261-5	2.7	7
104	Innovative therapy for chronic myelogenous leukemia. *Hematology/Oncology Clinics of North America*, **1998**, 12, 173-206	3.1	7
103	How killers kill. *Blood*, **2008**, 112, 213	2.2	7
102	FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab. *Blood*, **2019**, 134, 133-133	2.2	7
101	Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 618-622	4.7	7
100	Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 883-890	4.7	7
99	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. *Blood Advances*, **2021**, 5, 1069-1080	7.8	7
98	Fewer Circulating Natural Killer Cells 28 Days After Double Cord Blood Transplantation Predicts Inferior Survival and IL-15 Response. *Blood Advances*, **2016**, 1, 208-218	7.8	6
97	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. *Blood*, **2010**, 116, 225-225	2.2	6
96	CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics. *Blood*, **2016**, 128, 4291-4291	2.2	6
95	Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia. *Blood Advances*, **2019**, 3, 2448-2452	7.8	6
94	The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. *Blood Advances*, **2019**, 3, 2465-2469	7.8	6
93	CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL. *Cancer Immunology, Immunotherapy*, **2021**, 70, 3701-3708	7.4	6

92	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. *Bone Marrow Transplantation*, **2020**, 55, 1975-1984	4.4	5
91	Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. *Experimental Hematology*, **2000**, 28, 352	3.1	5
90	Ascorbic Acid Promotes Demethylation during Early NK Cell Differentiation. *Journal of Immunology*, **2020**, 205, 1513-1523	5.3	5
89	Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 949-954	4.7	5
88	A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer. *Cancers*, **2021**, 13,	6.6	5
87	KIR B or not to be?...that is the question for ALL. *Blood*, **2014**, 124, 2623-4	2.2	4
86	ADAM17, a Novel Metalloproteinase, Mediates CD16 and CD62L Shedding in Human NK Cells and Modulates IFN Responses. *Blood*, **2011**, 118, 2184-2184	2.2	4
85	Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia. *Blood*, **2011**, 118, 355-355	2.2	4
84	A Novel HIV Envelope Bi-Specific Killer Engager Enhances Natural Killer Cell Mediated ADCC Responses Against HIV-Infected Cells. *Blood*, **2016**, 128, 2517-2517	2.2	4
83	Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity. *Blood*, **2016**, 128, 551-551	2.2	4
82	Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation. *Frontiers in Immunology*, **2021**, 12, 711621	8.4	4
81	Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation. *Cancer Treatment and Research*, **2009**, 144, 497-537	3.5	4
80	Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. *American Journal of Hematology*, **2018**, 93, 1014	7.1	3
79	Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1925-1931	4.7	3
78	Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD). *Blood*, **2019**, 134, 804-804	2.2	3
77	NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death. *Blood*, **2019**, 134, 3215-3215	2.2	3
76	Natural Killer (NK) Cells Respond to CMV Reactivation After Allogeneic Transplantation with An Increase in NKG2C+CD57+ Self-KIR+ NK Cells with Potent IFN Production. *Blood*, **2011**, 118, 356-356	2.2	3
75	Ex Vivo Culture of CD34+/Lin/DR Cells in Stroma-Derived Soluble Factors, Interleukin-3, and Macrophage Inflammatory Protein-1 Maintains Not Only Myeloid But Also Lymphoid Progenitors in a Novel Switch Culture Assay. *Blood*, **1998**, 91, 4516-4522	2.2	3

74	Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 310.e1-310.e6		3
73	Following Transplantation for Acute Myelogenous Leukemia, Donor Better Protects against Relapse than. *Journal of Immunology*, **2021**,	5.3	3
72	Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C NK cells to target myeloid leukemia. *Molecular Therapy*, **2021**, 29, 3410-3421	11.7	3
71	Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. *Molecular Diagnosis and Therapy*, **2021**, 25, 577-592	4.5	3
70	Assessing Canonical and Adaptive Natural Killer Cell Function in Suppression Assays In Vitro. *Methods in Molecular Biology*, **2019**, 1913, 153-166	1.4	2
69	Clinical trials of NK cells for cancer **2010**, 555-570		2
68	A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma. *Blood*, **2020**, 136, 3-3	2.2	2
67	PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets. *Blood*, **2019**, 134, 621-621	2.2	2
66	Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells.. *Blood*, **2004**, 104, 260-260	2.2	2
65	Chronic Graft Versus Host Disease (cGVHD) Following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate in Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB).. *Blood*, **2005**, 106, 1814-1814	2.2	2
64	Dyskeratosis Congenita: Low Regimen-Related Toxicity Following Hematopoietic Cell Transplantation (HCT) Using a Reduced Intensity Conditioning Regimen.. *Blood*, **2007**, 110, 2005-2005	2.2	2
63	A Phase II Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 4307-4307	2.2	2
62	Immune Reconstitution after Umbilical Cord Blood Versus Peripheral Blood Progenitor Cell Transplantation in Adults Following Myeloablative Conditioning. *Blood*, **2016**, 128, 2246-2246	2.2	2
61	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. *Blood*, **2021**,	2.2	2
60	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia **2020**, 8,		2
59	Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. *Bone Marrow Transplantation*, **2018**, 53, 1069-1071	4.4	1
58	Natural Killer CellBased Therapies **2018**, 1575-1582		1
57	Human polymorphism and variable outcomes of cancer chemotherapy and transplantation. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 120-8	4.7	1

56	Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC. *Blood*, **2020**, 136, 10-11	2.2	1
55	First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2018**, 132, 2112-2112	2.2	1
54	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. *Blood*, **2018**, 132, 71-71	2.2	1
53	Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity. *Blood*, **2018**, 132, 4541-4541	2.2	1
52	Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma. *Blood*, **2020**, 136, 6-6	2.2	1
51	Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade. *Blood*, **2008**, 112, 2906-2906	2.2	1
50	Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2. *Blood*, **2012**, 120, 346-346	2.2	1
49	Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee. *Blood*, **2013**, 122, 159-159	2.2	1
48	Death Receptor 3 (DR3) Is Expressed By Innate Lymphoid Cells (ILC) and Ligation By Tumor Like Antigen-1 (TL1A) Leads To Costimulation and Significant ILC Expansion. *Blood*, **2013**, 122, 782-782	2.2	1
47	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. *Blood*, **2015**, 126, 2022-2022	2.2	1
46	In Vitro Induction of Human Regulatory T-Cells (iTregs) Using Conditions of Low Tryptophan Plus Kynurenines. *Blood*, **2016**, 128, 1229-1229	2.2	1
45	Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells. *Blood*, **2016**, 128, 503-503	2.2	1
44	Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation.. *Translational Oncology*, **2021**, 16, 101318	4.9	1
43	iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo. *Blood*, **2019**, 134, 1933-1933	2.2	1
42	A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy		1
41	FLT-3 Ligand and Marrow Stroma-Derived Factors Promote CD3□CD3□CD3□and RAG-2 Gene Expression in Primary Human CD34+LIN□DR□Marrow Progenitors. *Blood*, **1998**, 91, 1662-1670	2.2	1
40	Infusion reactions in natural killer cell immunotherapy: a retrospective review. *Cytotherapy*, **2021**, 23, 627-634	4.8	1
39	Activation status dictates the function of unlicensed natural killer cells in mice and humans. *Blood Advances*, **2021**, 5, 4219-4232	7.8	1

38	CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma. *Blood*, **2020**, 136, 34-35	2.2	0
37	Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM). *Blood*, **2019**, 134, 777-777	2.2	0
36	Comparison of IPSS and IPSS-R Scoring in a Population Based Myelodysplastic Syndromes (MDS) Study. *Blood*, **2012**, 120, 3841-3841	2.2	0
35	Therapeutic effect of TRC105 and decitabine combination in AML xenografts. *Heliyon*, **2020**, 6, e05242	3.6	0
34	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. *Cytotherapy*, **2021**, 23, 704-714	4.8	0
33	NK cells pave the road for alloengraftment. *Blood*, **2016**, 127, 1083-4	2.2	0
32	Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.. *Stem Cell Research and Therapy*, **2022**, 13, 165	8.3	0
31	Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state. *American Journal of Hematology*, **2017**, 92, E549-E552	7.1	
30	Natural Killer CellBased Immunotherapy **2018**, 215-227		
29	Natural killer cells in graft-versus-host disease and graft-versus-leukemia **2013**, 327-356		
28	Response: The role of G-CSF on the risk of graft-versus-host disease after donor lymphocyte infusions. *Blood*, **2008**, 111, 5256-5257	2.2	
27	Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML. *Blood*, **2020**, 136, 57-58	2.2	
26	ADAM17 and CD56low CD16low NK cells. *Haematologica*, **2015**, 100, e331	6.6	
25	Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 28, 61-61		
24	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. *Blood*, **2004**, 104, 2148-2148	2.2	
23	Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.. *Blood*, **2004**, 104, 1825-1825	2.2	
22	Human Embryonic Stem Cells Differentiate into Functional Natural Killer Cells with the Capacity To Mediate Anti-Tumor Activity.. *Blood*, **2005**, 106, 763-763	2.2	
21	C-MYC Induces KIR Expression Via a Novel Control Region Upstream of the Conventional Adult KIR Promoter.. *Blood*, **2005**, 106, 764-764	2.2	

20	Stromal Cells Support a Myeloid Pathway of Human NK Cell Differentiation.. *Blood*, **2007**, 110, 1336-1336	2.2
19	Cyclin-Dependent Kinases (CDK) Signaling Blockade Potentiates NK Cell Mediated Cytotoxicity Against Acute Myelogenous Leukemia. *Blood*, **2018**, 132, 4538-4538	2.2
18	Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS. *Blood*, **2018**, 132, 195-195	2.2
17	Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality. *Blood*, **2015**, 126, 147-147	2.2
16	Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (alloHCT): Comparing Results in Recipients of Unrelated Umbilical Cord Blood (UCB) to Those with an HLA-Matched Sibling Donor Peripheral Blood (MSD PB). *Blood*, **2016**, 128, 4590-4590	2.2
15	Tim-3, a Novel Immune Receptor, Is Constitutively Expressed on Human Natural Killer Cells and Functions as An Activating Coreceptor. *Blood*, **2010**, 116, 106-106	2.2
14	Impact of Graft Source on Immune Recovery: Comparions Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells.. *Blood*, **2010**, 116, 3731-3731	2.2
13	NK Education: Disassociation Between Recovery of Cytoxicity and Cytokine Production In NK Cells After Allogeneic Transplantation.. *Blood*, **2010**, 116, 1462-1462	2.2
12	IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,. *Blood*, **2011**, 118, 3611-3611	2.2
11	The Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplant Outcomes in Acute Myeloid Leukemia Patients,. *Blood*, **2011**, 118, 4148-4148	2.2
10	Combination Therapy with Vorinostat and Bortezomib in Patients with High Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. *Blood*, **2011**, 118, 4277-4277	2.2
9	Impact of Umbilical Cord Blood (UCB) T Regulatory Cells (Tregs) On Infection Risk Early After UCB Transplant. *Blood*, **2012**, 120, 4188-4188	2.2
8	Characterization Of a Weakly Expressed KIR2DL1 Allele. *Blood*, **2013**, 122, 4847-4847	2.2
7	Early NK Cell Proliferation After Umbilical Cord Blood Transplantation Is Associated With Superior Disease-Free Survival Due To Reduced Leukemia Relapse. *Blood*, **2013**, 122, 4610-4610	2.2
6	Adoptive immunotherapy **2016**, 479-487	
5	Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation **2016**, 126-138	
4	Cellular Immunotherapy-Highlights from TCT 2021. *Transplantation and Cellular Therapy*, **2021**, 27, 527-532	
3	Putting On the Gas and Taking Off the Brakes: A Novel Combinatorial Strategy to Enhance Tumor-Infiltrating Lymphocytes. *Cancer Immunology Research*, **2021**, 9, 1110	12.5

2	Quantitative serum PCR argues against long-term persistence of HHV-6 viremia after umbilical cord blood transplantation. *Transplant Infectious Disease*, **2021**, 23, e13555	2.7
1	Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation163-175	